Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 285 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR This Harmful Chemical Is Still Being Used In Popular Household Products June 15, 2021 New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... December 1, 2022 The Frontline Oncology Workforce Unites to Reduce the Burden of Cancer... September 9, 2022 Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... February 3, 2025 Load more HOT NEWS Metastatic Breast Cancer: ESMO Living Guideline Heine H. Hansen Award: Johan Vansteenkiste and Fiona Blackhall Honoured for... Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation
